E. Klouras, M. Elisaf
Abstract
Lipoprotein (a), consisting of an LDL particle linked to an apoprotein (a), is a unique particle with both atherogenic and prothrombotic properties. Elevated lipoprotein (a) levels are independently associated with higher cardiovascular risk, while their reduction is challenging. New lipid-lowering drugs, such as PCSK9 inhibitors, seem to reduce lipoprotein (a) levels, however, the underlying mechanismσ and the exact interaction between lipoprotein (a) and PCSK9 protein is not known.
Keywords: lipoprotein (a), protein PCSK9, PCSK9 inhibitors